News & Press Releases

Mintz Member Rachel Alexander shared insights with Bloomberg Law for an article about how employers are increasingly challenging state laws regulating pharmacy benefit managers (PBM). The piece focuses on the Supreme Court’s recent decision not to review Oklahoma’s Patient’s Right to Pharmacy Choice Act, which the Tenth Circuit had struck down for violating ERISA. While the ruling applies only to the six states under the Tenth Circuit, it may influence similar cases nationwide.

Mintz Member Alexandra Gallo-Cook was quoted by The Deal in an article about a bill that would give New York jurisdiction over a wide array of mergers. If enacted, New York would have the most far-reaching competition law of any state.

San Francisco Business Times featured Mintz’s new office lease in San Francisco at 525 Market St. The firm will be increasing its footprint in downtown by 50% to 29,000 square feet on a whole single floor with the new space.

Fiduciary News quoted Of Counsel Michelle Capezza in an article about how even though ERISA does not address cybersecurity in its original 1974 text, it requires fiduciaries to act prudently in managing and protecting 401k plans. The DOL issued guidance for 401k plan sponsors in 2021 and 2024, which explicitly ties cybersecurity to fiduciary responsibilities.

Mintz advised the underwriters in connection with a $230 million public offering by Cogent Biosciences, Inc. of 25,555,556 shares of common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses.

Mintz advised the underwriters in connection with a $200 million public offering by Soleno Therapeutics, Inc. of 2,352,941 shares of its common stock at a price to the public of $85.00 per share.  The gross proceeds to Soleno from the offering were approximately $200 million before deducting underwriting discounts and commissions and other offering expenses. In addition, Soleno granted the underwriters a 30-day option to purchase up to an additional 352,941 shares of its common stock at the public offering price.